drugset / Trial / NCT02270463
SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission
NaSingle-groupOpen-labelTreatment
Summary
This is a non-randomized, open-label, multicenter, dose escalation study designed to determine the maximum tolerated dose (MTD) of SL-401 in adult patients with acute myeloid leukemia, and to evaluate the safety profile of SL-401 at the MTD.
Timeline
- Start
- 2015-02
- Primary completion
- 2019-12
- Completion
- 2019-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tagraxofusp | Protein / enzyme biologic | 7 ug/kg | Intravenous |
| Subject | Tagraxofusp | Protein / enzyme biologic | 9 ug/kg | Intravenous |
| Subject | Tagraxofusp | Protein / enzyme biologic | 12 ug/kg | Intravenous |